South Korea Car-T Cell Therapy Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
South Korea Car-T Cell Therapy Market is Segmented By Targeted Antigen (CD19, CD20, BCMA, GCP-3, Claudin 18.2), By Therapeutic Application (B-cell non-Hodgkin\'s lymphoma, Multiple Myeloma, Cervical Cancer, Gastric Cancer, Lung Cancer, Others). The report offers the value (in USD Million) for the above-mentioned segments
Competitive overview of South Korea Car-T Cell Therapy Market
Les principaux acteurs du marché sud-coréen de la thérapie cellulaire automobile sont Novartis AG, Pfizer, Inc., Bristol Myers Squibb, CARsgen Therapeutics Co., Ltd., Fate Therapeutics, Inc., Poseida Therapeutics, Inc., Eureka Therapeutics, Inc., Johnson & Johnson, Cellular Biomedicine Group et Gilead Sciences, Inc.
South Korea Car-T Cell Therapy Market Leaders
- Novartis AG
- La société Pfizer, Inc.
- Bristol Myers Squibb
- La société CARsgen Therapeutics Co., Ltd.
- Le destin thérapeutique, Inc.
*Disclaimer: Major players are listed in no particular order.
South Korea Car-T Cell Therapy Market - Competitive Rivalry, 2023
South Korea Car-T Cell Therapy Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights